----
Current ValuationThe current P/E ratio is -0.64, within the reasonable range, cheaper than 68.46% of the time in the past 1 years, and the industry ranks 16/39, the industry Median -0.77.
-0.638xP/E
$0.73Stock price
$-1.14Earnings per share
-0.638xP/E
Stock price$0.73Earnings per share$-1.14
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -0.37x
- Typical range
- -1.94x–-0.15x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
011223344
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
HTFLUSHeartFlow | -36.23x | 76.19% | $4.29B |
SDGRUSSchrodinger | -41.73x | 13.66% | $2.27B |
CERTUSCertara | -20.87x | 1,962.60% | $1.43B |
TDOCUSTeladoc | -5.65x | 22.88% | $1.00B |
MDRXUSVeradigm | -- | -- | $851.43M |
SOPHUSSophia Genetics SA | -8.49x | 19.83% | $686.98M |
CTEVUSClaritev | -1.42x | 12.62% | $401.99M |
EVHUSEvolent Health | -0.77x | 84.41% | $391.19M |
AMWLUSAmerican Well | -2.70x | 57.74% | $210.74M |
DHUSDefinitive Healthcare | -0.80x | 28.60% | $135.18M |
LFMDUSLifeMD | -45.46x | 195.82% | $132.07M |
HCATUSHealth Catalyst | -0.50x | 4.22% | $131.70M |
DRIOUSDarioHealth | -9.04x | 62.43% | $63.27M |
RNLXYUSRENALYTIX PLC SPON ADS EACH REP 50 ORD (POST SPLIT) | -2.43x | -- | $48.31M |
ONMDUSOneMedNet | -3.79x | -- | $31.96M |
ITOCUSiTonic | -3.27x | -- | $29.15M |
AIFFUSFirefly Neuroscience | -2.26x | -- | $21.34M |
BFRGUSBullfrog AI | -1.91x | 41.27% | $11.45M |
HCTIUSHealthcare Triangle | -0.64x | 93.28% | $10.86M |
ACONUSAclarion | -0.75x | 65.17% | $6.86M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
